Opus Genetics Inc reports results for the quarter ended September 30 - Earnings Summary

Opus Genetics

12/11/2024 15:32

* Opus Genetics Inc  IRD.OQ  reported a quarterly adjusted
loss
of 29 cents​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of 25 cents.  The mean expectation of four analysts for the
quarter was for a loss of 24 cents per share. Wall Street
expected results to range from -30 cents to -10 cents per share.
    * Revenue fell 67.6% to $3.87 million from a year ago;
analysts
expected $2.29 million. 
    * Opus Genetics Inc's reported EPS for the quarter was a
loss
of 29 cents​.
    * The company reported a quarterly loss of $7.53 million.
    * Opus Genetics Inc shares had fallen by 10.7% this
quarter and
lost 61.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 5% in
the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Opus Genetics Inc
is $10.00 
This summary was machine generated from LSEG data November 12 at
03:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.24          -0.29          Missed
 Jun. 30 2024      -0.25          -0.30          Missed
 Dec. 31 2023      -0.13          -0.29          Missed
 Dec. 31 2023      -0.05          -0.21          Missed